Inflammatory bowel disease (IBD) afflicts 5 million people and is increasing in prevalence. There is an unmet clinical need for safer and effective treatments for IBD. The BT-11 is a small molecule oral therapeutic that ameliorates IBD by targeting lanthionine synthetase C-like 2 (LANCL2) and has a benign safety profile in rats.
New Data Presented at IMMUNOLOGY2026 Shows LANCL2 Medicines in Clinical Development for IBD Can Provide Protection from Asthma
New Data Presented at IMMUNOLOGY2026 Shows LANCL2 Medicines in Clinical Development for IBD Can Provide Protection from Asthma
NImmune Biopharma, Inc is pleased to share the release of exciting new data on the efficacy of LANCL2 medicines in treating inflammatory diseases and their immunometabolic mechanisms of action at The American Association of Immunologists Annual Meeting,...
